Testing spironolactone for treating alcohol use disorder

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effects of spironolactone, a medication typically used for high blood pressure, on individuals with alcohol use disorder (AUD). Participants will undergo four separate 7-day stays at a clinic in Baltimore, where they will take spironolactone capsules twice daily for five days. The study will assess how spironolactone interacts with alcohol in the body, focusing on its pharmacokinetics and pharmacodynamics, as well as monitoring safety and tolerability. The goal is to determine if spironolactone can be an effective treatment for reducing alcohol consumption in people with AUD.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:

In order to be eligible to enroll in this study, an individual must meet all of the following criteria:

1. At least 21 years old
2. Alcohol Use Disorder (minimum 2 symptoms on a validated diagnostic tool, e.g., the Mini- International Neuropsychiatric Interview (MINI) or the Structured Clinical Interview for DSM Disorders (SCID))
3. At least four days with \>= 4 drinks for females or \>= 5 drinks for males during the 28-day period prior to screening, according to alcohol TimeLine Follow Back (TLFB)
4. Most recent Clinical Institute Withdrawal Assessment for Alcohol - revised (CIWA-Ar) score is \< 10
5. Able to speak, read, write, and understand English as demonstrated by their ability to understand and sign the consent for the NIDA screening protocol.
6. Female participants must be postmenopausal for at least one year, surgically sterile, or practicing a highly effective method of birth control before entry and throughout the study and must have negative pregnancy tests at each stage. Examples of highly effective methods of birth control include abstinence, hormonal contraceptives (e.g., certain birth control pills, contraceptive patch, vaginal ring, or implants), intrauterine device (IUD), tubal ligation, or vasectomy.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Most recent blood tests: potassium \> 5.2 mmol/L; creatinine \>= 2 mg/dL; eGFR \< 60 mL/min/1.73 m\^2, hemoglobin A1c (HbA1c) \> 6.5 %
2. Clinically significant and/or symptomatic hyponatremia, hypomagnesemia, hypocalcemia, and hyperuricemia based on Medical Advisory Investigators (MAI) or designee judgment.
3. Known history of clinically significant orthostatic hypotension
4. Known history of hypoaldosteronism, hyperaldosteronism, Addison s disease
5. Diagnosis of NYHA class III-IV heart failure, or unstable cardiovascular conditions (e.g., arrhythmias, clinically significant ECG abnormalities)
6. Current use of any diuretic, angiotensin receptor blocker (ARB), angiotensin converting enzyme inhibitor (ACEI), potassium supplementation, potassium containing salt substitute, heparin and low molecular weight heparin (LMWH), trimethoprim, lithium, digoxin, cholestyramine
7. Current use of MR antagonists
8. Current use of FDA-approved pharmacotherapy for AUD, or seeking treatment for AUD
9. Known history of prior hypersensitivity reaction to spironolactone or other MR antagonists, or any of the product components
10. Known history of alcohol withdrawal seizure and delirium tremens.
11. Physical and/or mental health conditions that are clinically unstable, as determined by the study clinicians, including (but not limited to) major depressive disorder or generalized anxiety disorder unstable during the past three months or other psychiatric conditions (e.g., schizophrenia, bipolar disorder) unstable during the past twelve months prior to screening.
12. Pregnancy, intention to become pregnant, or breastfeeding.
13. Any other reason or clinical condition that the Investigators judge would interfere with study participation and/or be unsafe for a participant.

Where it's running

• National Institute on Drug Abuse
  Baltimore, Maryland, United States Recruiting

Study contacts

• Principal investigator: Lorenzo Leggio, M.D. — National Institute on Drug Abuse (NIDA)
• Study coordinator: Masoumeh Dejman
• Email: masoumeh.dejman@nih.gov
• Phone: (240) 987-8983

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Emotional Reactivity in Severe Alcohol Use Disorder and Depression Using Eye-Tracking and Physiological Measures

  This study tests how people with severe alcohol use disorder, major depressive disorder, both conditions, or neither, recognize and react to emotions using eye-tracking and physiological data.

  Recruiting Université Catholique de Louvain · Brussels, Belgium · NCT07925281

• Thiamine to reduce brain injury in adults with alcohol use disorder

  This trial tests whether thiamine can help protect the brain in adults with moderate to severe alcohol use disorder who drink daily.

  Recruiting Phase 2 Institut National de la Santé Et de la Recherche Médicale, France · Paris, Île-de-France Region · NCT07844720

• Digital Recovery Support for Black adults with Alcohol Use Disorder in Detroit

  This study tests whether a smartphone-based digital recovery program helps Black or African American adults in Detroit maintain their recovery from alcohol use disorder.

  Recruiting Brandeis University · Detroit, Michigan · NCT07724275

• Path180: a computer-based skills program to help teens reduce alcohol use

  This 8-week trial tests Path180, a computer-based skills training, added to usual care for teens 13–19 with alcohol use disorder to see if it improves daily-life coping skills and outcomes.

  Recruiting Brown University · Providence, Rhode Island · NCT07713251

• Effects of comorbidity on people with severe mental illness

  This study tests how having both alcohol/substance use and a severe mental illness affects hospitalizations, medications, and social participation among adults followed at a mental health center.

  Recruiting Abant Izzet Baysal University · Bolu, Bolu · NCT07692984

• Psilocybin in Alcohol Use Disorder with Depression (Relapse Prevention)

  This study tests whether higher-dose psilocybin-assisted psychotherapy helps prevent relapse in adults with severe alcohol use disorder and depressive symptoms after detox.

  Recruiting Phase 3 Centre Hospitalier Universitaire de Nīmes · Bayonne and 7 other locations · NCT07638553

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.